Amylyx Pharmaceuticals
Amylyx is seeking a Director, Launch Excellence to lead preparation for the commercial launch of its first endocrinology product, partnering across functions to ensure organizational readiness for a potential 2027 launch. The role will act as the central coordinator for launch activities within a clinical-stage biotechnology company focused on high unmet-need diseases. This position will be hired in 2026 and is based in the U.S., with regular in-person presence expected in Cambridge, MA.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet needs, including Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Amyotrophic Lateral Sclerosis (ALS). Its lead program, Avexitide, is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial for PBH. Amylyx advances its pipeline using rigorous science, well-defined mechanistic rationale, and a strong commitment to the patient communities it serves.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amylyx Pharmaceuticals.
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating
4 days ago